Skip to main content

Advertisement

SpringerLink
Log in

Raynaud’s phenomenon

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Treatment of Raynaud’s phenomenon in any one individual depends on the severity of symptoms and whether or not there is an underlying disease process requiring specific intervention. Many patients with primary (idiopathic) Raynaud’s phenomenon respond well to treatment with general measures, perhaps with the addition of a calcium channel blocker. Conversely, others with underlying structural vascular abnormality (as occurs in connective tissue diseases such as systemic sclerosis [SSc]) are often refractory to treatment and may progress to irreversible tissue injury, sometimes with gangrene. Because these patients are the most challenging and because a large proportion of the research into Raynaud’s phenomenon has been conducted in patients with SSc-spectrum disorders, much of this review is weighted toward them. The key principles of management are removal/treatment of any triggering factor/underlying cause, general (nondrug) measures, drug treatment, and surgery, although the last is rarely indicated. New insights into pathogenesis have led, and continue to lead, to new approaches to treatment, including endothelin-1 receptor antagonism and nitric oxide supplementation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Raynaud M: Local Asphyxia and Symmetrical Gangrene of the Extremities 1862. New Researches on the Nature and Treatment of Local Asphyxia of the Extremities 1874. Translated by Barlow T. London: New Sydenham Society; 1888.

    Google Scholar 

  2. Wigley FM: Raynaud’s phenomenon. N Eng J Med 2002, 347:1001–1008.

    Article  Google Scholar 

  3. Herrick AL: Pathogenesis of Raynaud’s phenomenon. Rheumatology 2005, 44:587–596.

    Article  PubMed  CAS  Google Scholar 

  4. Fishman AP: Pulmonary hypertension-beyond vasodilator therapy. N Eng J Med 1998, 338:321–322.

    Article  CAS  Google Scholar 

  5. Chrysant SG: Vascular remodeling: the role of angiotensin-converting enzyme inhibitors. Am Heart J 1998, 135:S21–S30.

    Article  PubMed  CAS  Google Scholar 

  6. Kirchengast M, Münter K: Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999, 221:312–325.

    Article  PubMed  CAS  Google Scholar 

  7. Campbell PM, LeRoy EC: Pathogenesis of systemic sclerosis: a vascular hypothesis. Sem Arthritis Rheum 1975, 4:351–368.

    Article  CAS  Google Scholar 

  8. Rodnan GP, Myerowitz RL, Justh GO: Morphological changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine 1980, 59:393–408.

    Article  PubMed  CAS  Google Scholar 

  9. Harrison BJ, Silman AJ, Hider SL, Herrick AL: Cigarette smoking: a significant risk factor for digital vascular disease in patients with systemic sclerosis. Arthritis Rheum 2002, 46:3312–3316.

    Article  PubMed  Google Scholar 

  10. Raynaud’s Treatment Study Investigators: Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med 2000, 160:1101–1108.

    Article  Google Scholar 

  11. Kahaleh MB, Osborn I, LeRoy EC: Elevated levels of circulating platelet aggregates and beta-thromboglobulin in scleroderma. Ann Int Med 1982, 96:610–613.

    PubMed  CAS  Google Scholar 

  12. Merkel PA, Herlyn K, Martin RW, et al.: Measuring disease activity and functional status in patients with scleroderma and Raynaud’s phenomenon. Arthritis Rheum 2002, 46:2410–2420.

    Article  PubMed  Google Scholar 

  13. Korn JH, Mayes M, Matucci Cerinic M, et al.: for the RAPIDS-1 Study Group: Digital ulcers in systemic sclerosis. Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985–3993.

    Article  PubMed  CAS  Google Scholar 

  14. Gliddon AE, Dor’e CJ, Black CM, et al.: Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon: a randomised controlled trial of the ACE-inhibitor quinapril. Arthritis Rheum 2007, 56:3837–3846.

    Article  PubMed  CAS  Google Scholar 

  15. Malamet R, Wise RA, Ettinger WH, Wigley FM: Nifedipine in the treatment of Raynaud’s phenomenon. Evidence for inhibition of platelet activation. Am J Med 1985, 78:602–608.

    Article  PubMed  CAS  Google Scholar 

  16. Allanore Y, Borderie D, Lemarechal H, et al.: Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med 2004, 116:595–600.

    Article  PubMed  CAS  Google Scholar 

  17. Thompson AE, Pope JE: Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology 2005, 44:145–150.

    Article  PubMed  CAS  Google Scholar 

  18. Thompson AE, Shea B, Welch V, et al.: Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum 2001, 44:1841–1847.

    Article  PubMed  CAS  Google Scholar 

  19. Dziadzio M, Denton CP, Smith R, et al.: Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999, 42:2646–2655.

    Article  PubMed  CAS  Google Scholar 

  20. Pope J, Fenlon D, Thompson A, et al.: Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000956.

  21. Pope J, Fenlon D, Thompson A, et al.: Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000953.

  22. Wigley FM, Korn JH, Csuka ME, et al.: Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multi-center, placebo-controlled, double-blind study. Arthritis Rheum 1998, 41:670–677.

    Article  PubMed  CAS  Google Scholar 

  23. Vayssairat M: Preventative effect of an oral prostacyclin analog, beroprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes. J Rheumatol 1999, 26:2173–2178.

    PubMed  CAS  Google Scholar 

  24. Wigley FM, Wise RA, Seibold JR, et al.: Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, doubleblind study. Ann Intern Med 1994, 120:199–206.

    PubMed  CAS  Google Scholar 

  25. Seibold JR, Matucci-Cerinic M, Denton CP, et al.: Bosentan reduces the number of new digital ulcers in patients with systemic sclerosis [abstract]. Ann Rheum Dis 2006, 65(Suppl II):90.

    Google Scholar 

  26. Pope J, Fenlon D, Thompson A, et al.: Ketanserin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998, CD000954.

  27. Coleiro B, Marshall SE, Denton CP, et al.: Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology 2001, 40:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  28. Yee AM, Hotchkiss RN, Paget SA: Adventitial stripping: adigit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol 1998, 25:269–276.

    PubMed  CAS  Google Scholar 

  29. McCall TE, Petersen DP, Wong LB: The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud’s disease and phenomenon. J Hand Surg [Am] 1999, 24:173–177.

    Article  CAS  Google Scholar 

  30. Tomaino MM, Goitz RJ, Medsger TA: Surgery for ischemic pain and Raynaud’s phenomenon in scleroderma: a description of treatment protocol and evaluation of results. Microsurgery 2001, 21:75–79.

    Article  PubMed  CAS  Google Scholar 

  31. Kotsis SV, Chung KC: A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol 2003, 30:1788–1792.

    PubMed  Google Scholar 

  32. Taylor MH, McFadden JA, Bolster MB, Silver RM: Ulnar artery involvement in systemic sclerosis (scleroderma). J Rheumatol 2002, 29:102–106.

    PubMed  CAS  Google Scholar 

  33. Klyscz T, Junger M, Meyer H, Rassner G: Improvement of acral circulation in a patient with systemic sclerosis with stellate blocks. Vasa 1998, 27:39–42.

    PubMed  CAS  Google Scholar 

  34. Veale DJ, Collidge TA, Belch JJF: Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995, 54:853–855.

    Article  PubMed  CAS  Google Scholar 

  35. Teh LS, Manning J, Moore T, et al.: Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud’s phenomenon. Br J Rheumatol 1995, 34:636–641.

    Article  PubMed  CAS  Google Scholar 

  36. Khan F, Greig IR, Newton DJ, et al.: Skin blood flow after transdermal S-nitrosothio-acetylglucose. Lancet 1997, 350:410–411.

    Article  PubMed  CAS  Google Scholar 

  37. Tucker AT, Pearson RM, Cooke ED, Benjamin N: Effect of nitric-oxide-generating system on microcirculatory blood flow in skin in patients with severe Raynaud’s syndrome: a randomised trial. Lancet 1999, 354:1670–1675.

    Article  PubMed  CAS  Google Scholar 

  38. Anderson ME, Moore TL, Hollis S, et al.: Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology 2002, 41:324–328.

    Article  PubMed  CAS  Google Scholar 

  39. Chung L, Baron M, Collier D, et al.: A multi-center placebo-controlled “in-life” study of MQX-503 in patients with Raynaud’s phenomenon [abstract]. Arthritis Rheum 2007, 56(Suppl):S824.

    Google Scholar 

  40. Kumana CR, Cheung GTY, Lau CS: Severe digital ischaemia treated with phosphodiesterase inhibitors. Ann Rheum Dis 2004, 63:1522–1524.

    Article  PubMed  CAS  Google Scholar 

  41. Fries R, Shariat K, von Wilmowsky H, Bohm M: Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 2005, 112:2980–2985.

    PubMed  CAS  Google Scholar 

  42. Gore J, Silver R: Oral sildenafil for the treatment of Raynaud’s phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis 2005, 64:1387.

    Article  PubMed  CAS  Google Scholar 

  43. Caglayan E, Huntegeburth M, Karasch T, et al.: Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Int Med 2006, 166:231–233.

    Article  CAS  Google Scholar 

  44. Rajagopalan S, Pfenninger D, Somers E, et al.: Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol 2003, 92:1310–1315.

    Article  PubMed  CAS  Google Scholar 

  45. Herrick AL, Matucci Cerinic M: The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4–8.

    PubMed  CAS  Google Scholar 

  46. Denton CP, Bunce TD, Dorado MB, et al.: Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology 1999, 38:309–315.

    Article  PubMed  CAS  Google Scholar 

  47. Herrick AL, Hollis S, Schofield D, et al.: A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 2000, 18:349–356.

    PubMed  CAS  Google Scholar 

  48. Beckett VL, Conn DL, Fuster V, et al.: Trial of platelet-inhibiting drug in scleroderma. Arthritis Rheum 1984, 27:1137–1143.

    Article  PubMed  CAS  Google Scholar 

  49. Chotani MA, Flavahan S, Mitra S, et al.: Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000, 278:H1075–H1083.

    PubMed  CAS  Google Scholar 

  50. Wise RA, Wigley FM, White B, et al.: Efficacy and tolerability of a selective alpha(2C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients. A single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum 2004, 50:3994–4001.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK

    Ariane Herrick

Authors
  1. Ariane Herrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariane Herrick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Herrick, A. Raynaud’s phenomenon. Curr Treat Options Cardio Med 10, 146–155 (2008). https://doi.org/10.1007/s11936-008-0016-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-008-0016-y

Keywords

Search

Navigation